Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Bank of America to “Neutral”

Bank of America upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRYFree Report) from an underperform rating to a neutral rating in a report issued on Friday morning, Marketbeat reports.

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They issued a neutral rating on the stock. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Hold.

Get Our Latest Research Report on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Price Performance

OTCMKTS:BAYRY opened at $8.01 on Friday. The stock’s 50-day simple moving average is $7.40 and its 200 day simple moving average is $7.43. Bayer Aktiengesellschaft has a 52-week low of $6.82 and a 52-week high of $13.82. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The company has a market cap of $31.48 billion, a P/E ratio of -9.21 and a beta of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.25. The company had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.37 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

Featured Articles

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.